Endometriosis is generally associated with an immunoinflammatory process that takes place in the peritoneal cavity of patients. Interleukin (IL)-6, a multifunctional cytokine involved in numerous immunological and proliferative processes, h…
Before treatment, the trabecular bone mineral content of the lumbar spine and femoral neck was not significantly different between endometriosis patients and age-matched controls (N = 26). In 17 subjects treated with a monthly goserelin imp…
OBJECTIVE: The evaluation of cholesterol fractions and apoproteins during ovarian suppression by a GnRH agonist implant vs danazol in the treatment of endometriosis. DESIGN: A randomized study in 33 patients comparing goserelin (3.6 mg/4 w…
We have previously reported reversible hypogonadism induced by the intranasal administration of the luteinizing hormone-releasing hormone agonist buserelin as a new therapeutic approach for endometriosis. Thirteen patients were randomized t…
Six endometriosis patients were treated with continuous subcutaneous (SC) infusion of a luteinizing hormone-releasing hormone (LH-RH) agonist using an external osmotic minipump system. Serum estradiol (E2) was suppressed into the menopausal…
Reversible down-regulation of pituitary-ovarian function induced by repetitive LH-RH agonist administration as a new approach for treatment and study of endometriosis in the human was published in LH-RH and its Analogues on page 337.